MedTrace Logo

Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America

NCT00312663 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2018-11-26

Study results available
· View outcomes & findings →

Summary

Phase I/II Trial of a Malaria Vaccine, FMP011/AS01B, in Adults Living in the United States of America.

Conditions

  • Plasmodium Falciparum Malaria

Interventions

BIOLOGICAL

Falciparum Malaria Protein 11 with AS01B adjuvant.

malaria experimental vaccine

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • The PATH Malaria Vaccine Initiative (MVI)

    collaborator OTHER

  • Walter Reed Army Institute of Research (WRAIR)

    collaborator FED

  • U.S. Army Medical Research and Development Command

    lead FED

Principal Investigators

  • James F. Cummings, MD · Walter Reed Army Institute of Research (WRAIR)

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2006-10-31
Completion
2007-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00312663 on ClinicalTrials.gov